Fig. 2From: Efficacy and safety of PD-1/PD-L1 inhibitors combined with anti-angiogenic therapy for the unresectable hepatocellular carcinoma and the benefit for hepatitis B virus etiology subgroup: a systematic review and meta-analysis of randomized controlled trialsForest plots of OS (A) and PFS (B) of combination therapy with ICIs and anti-angiogenic drugsBack to article page